Developer docs
API playgroundTry for free, no card

Search company profiles

D3 Bio

Full company profile

uuid0000unz

Namestring
D3 Bio
Legal namestring
D3 Bio, Inc.
Websiteurl
d3bio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

D3 Bio is a clinical-stage biotechnology company founded in November 2020 and headquartered in Shanghai with R&D operations in Wuxi, China. The company develops precision oncology therapeutics, with its lead asset elisrasib (D3S-001) being a next-generation GDP-bound KRAS G12C inhibitor that covalently binds the OFF form of KRAS G12C to abolish nucleotide cycling between RAS Off and RAS On states, demonstrating rapid and complete target engagement, CNS penetration, and a favorable safety profile. The company is advancing elisrasib into global Phase III pivotal trials as monotherapy and in combination with pembrolizumab and an internal ERK1/2 inhibitor (D3S-002) for KRAS G12C-mutant non-small cell lung cancer, colorectal cancer, and pancreatic cancer across the United States, China, and the European Union.

The pipeline extends beyond elisrasib to include D3S-002, an ERK1/2 kinase inhibitor for vertical MAPK-pathway inhibition; D3S-003, a KRAS G12D inhibitor targeting the broader KRAS-mutant population; and D3L-001, a HER2×CD47 bispecific antibody for HER2-positive solid tumors. The company has secured FDA Fast Track Designation (2022), Orphan Drug Designations for pancreatic and colorectal cancers, and Breakthrough Therapy Designation for NSCLC (2025). Phase 2 first-line NSCLC data presented at ASCO 2026 reported 78.0% objective response rate for elisrasib monotherapy and 81.3% ORR for elisrasib plus pembrolizumab. D3 Bio owns global rights to all programs.

The business model is a traditional clinical-stage biotech commercialization pathway: develop innovative oncology therapeutics through clinical trials to regulatory approval, then commercialize globally via standard pharmaceutical distribution. The company is currently pre-revenue, funded by venture capital rather than product sales. Since launch D3 Bio has raised $370 million across a Series A ($200M, November 2020), a Series A+ led by Medicxi (April 2024), and a Series B ($108M, December 2025) with a syndicate including Temasek, WuXi AppTec, Boyu Capital, Matrix Partners China, Sequoia Capital China/HongShan, Medicxi, IDG Capital, HSG, MPCi, and SongQing Capital. Leadership is anchored by founder/CEO George Chen, MD (ex-AstraZeneca, 70+ INDs and 30+ NDAs directed) and co-founder/CFO/CBO John Jin, PhD (ex-BeiGene), with Antoine Yver, MD (former Daiichi Sankyo EVP) on the board.

Short descriptiontext

D3 Bio is a clinical-stage biotechnology company developing next-generation KRAS inhibitors and targeted oncology therapeutics. Headquartered in Shanghai with R&D in Wuxi, China, it is advancing its lead asset elisrasib into global Phase III trials for KRAS G12C-mutant lung, colorectal, and pancreatic cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWuxi Shi, China
HQ citystring
Wuxi Shi
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, KRAS inhibitor therapy, targeted cancer therapeutics, clinical-stage biotechnology, precision oncology medicines
Industry3 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, D3 Bio's revenue model is based on developing and commercializing innovative oncology therapeutics. The company is advancing its pipeline through clinical trials toward regulatory approvals for global commercialization. The company owns global rights to all programs.

d3bio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

D3 Bio is a clinical-stage biotechnology company developing precision oncology therapeutics, with lead asset elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor in global Phase III trials. The pipeline also includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody), each targeting tumor-driving mutations or immune pathways.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

D3 Bio is a clinical-stage biotechnology company developing a pipeline of oncology therapeutics targeting KRAS mutations and immune pathways. The core product is Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. The pipeline includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody). All programs target driver mutations or critical immune pathways with first-in-class or best-in-class potential, and D3 Bio owns global rights to all programs.

Product and service4 records
1Elisrasib (D3S-001)
CategoryCore product
Description

Next-generation GDP-bound KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. Covalently binds the GDP-bound (OFF) form of KRAS G12C, blocking nucleotide cycling and suppressing oncogenic signaling. Being evaluated in global Phase II/III clinical trials for NSCLC, CRC, and pancreatic cancer.

2D3S-002
CategoryPipeline product
Description

ERK1/2 inhibitor for vertical inhibition of the MAPK pathway to improve anti-tumor activity and overcome resistance to KRAS G12C inhibitors. IND cleared by FDA.

3D3S-003
CategoryPipeline product
Description

KRAS G12D inhibitor for KRAS-driven cancers. FDA IND cleared for Phase 1 trial.

4D3L-001
CategoryPipeline product
Description

HER2×CD47 bispecific antibody that enhances phagocytosis and eradication of HER2-positive solid tumors via HER2 guided CD47 co-blocking. IND cleared by FDA for Phase 1 trial.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed Krazati (adagrasib), a KRAS G12C inhibitor that received accelerated FDA approval in December 2022 for NSCLC and is in development for CRC and other KRAS G12C-mutated tumors. Mirati is the most direct mechanistic competitor to elisrasib in the same target and indication space.

TypeBroad incumbent
Description

Developed Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor (May 2021), with established commercial infrastructure in oncology. As the incumbent in KRAS G12C, Amgen represents the primary benchmark for elisrasib's clinical and commercial performance.

TypeDirect peer
Description

Clinical-stage oncology biotech developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C(ON)), which target the active GTP-bound state of RAS. Its next-generation mechanism could leapfrog elisrasib's GDP-bound approach.

TypeDirect peer
Description

Clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway, including ERK inhibitors and KRAS-targeting agents. Erasca's pipeline focus on the same signaling pathway makes it a direct mechanistic peer to D3 Bio's MAPK cascade strategy.

TypeEmerging player
Description

Through its oncology subsidiary has pipeline programs targeting KRAS and the MAPK pathway. BridgeBio's clinical-stage KRAS efforts overlap with D3 Bio's vertical MAPK inhibition strategy.

TypeBroad incumbent
Description

Global pharmaceutical company with major oncology franchise and established KRAS programs (including Datroway and earlier-stage assets). D3 Bio's leadership including George Chen and Antoine Yver previously held senior oncology roles at AstraZeneca, providing direct relevance to its development approach.

TypeRegional player
Description

Chinese-founded global oncology biotech with deep China-US clinical development capabilities, including Brukinsa (zanubrutinib). BeiGene shares the same founder/leadership DNA (George Chen and John Jin previously held senior roles at BeiGene) and similar global ambitions from a Chinese base.

TypeRegional player
Description

Chinese clinical-stage biotech developing oncology therapeutics including PD-1 and KRAS-targeted therapies, with global development ambitions. Comparable as a China-anchored oncology biotech pursuing US/EU regulatory pathways.

TypeRegional player
Description

Chinese clinical-stage biotech with oncology pipeline including the PD-1 toripalimab and KRAS-targeting programs. Comparable as a Chinese biotech pursuing global oncology development and US regulatory approvals.

TypeRegional player
Description

China-US biotech developing and commercializing innovative oncology therapeutics globally, including licensed and proprietary assets. Comparable business model as a Chinese-anchored oncology company pursuing US/China dual development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

D3 Bio

Oncology Therapeuticsd3bio.com

D3 Bio is a clinical-stage biotechnology company developing next-generation KRAS inhibitors and targeted oncology therapeutics. Headquartered in Shanghai with R&D in Wuxi, China, it is advancing its lead asset elisrasib into global Phase III trials for KRAS G12C-mutant lung, colorectal, and pancreatic cancers.

What D3 Bio does

D3 Bio is a clinical-stage biotechnology company founded in November 2020 and headquartered in Shanghai with R&D operations in Wuxi, China. The company develops precision oncology therapeutics, with its lead asset elisrasib (D3S-001) being a next-generation GDP-bound KRAS G12C inhibitor that covalently binds the OFF form of KRAS G12C to abolish nucleotide cycling between RAS Off and RAS On states, demonstrating rapid and complete target engagement, CNS penetration, and a favorable safety profile. The company is advancing elisrasib into global Phase III pivotal trials as monotherapy and in combination with pembrolizumab and an internal ERK1/2 inhibitor (D3S-002) for KRAS G12C-mutant non-small cell lung cancer, colorectal cancer, and pancreatic cancer across the United States, China, and the European Union.

The pipeline extends beyond elisrasib to include D3S-002, an ERK1/2 kinase inhibitor for vertical MAPK-pathway inhibition; D3S-003, a KRAS G12D inhibitor targeting the broader KRAS-mutant population; and D3L-001, a HER2×CD47 bispecific antibody for HER2-positive solid tumors. The company has secured FDA Fast Track Designation (2022), Orphan Drug Designations for pancreatic and colorectal cancers, and Breakthrough Therapy Designation for NSCLC (2025). Phase 2 first-line NSCLC data presented at ASCO 2026 reported 78.0% objective response rate for elisrasib monotherapy and 81.3% ORR for elisrasib plus pembrolizumab. D3 Bio owns global rights to all programs.

The business model is a traditional clinical-stage biotech commercialization pathway: develop innovative oncology therapeutics through clinical trials to regulatory approval, then commercialize globally via standard pharmaceutical distribution. The company is currently pre-revenue, funded by venture capital rather than product sales. Since launch D3 Bio has raised $370 million across a Series A ($200M, November 2020), a Series A+ led by Medicxi (April 2024), and a Series B ($108M, December 2025) with a syndicate including Temasek, WuXi AppTec, Boyu Capital, Matrix Partners China, Sequoia Capital China/HongShan, Medicxi, IDG Capital, HSG, MPCi, and SongQing Capital. Leadership is anchored by founder/CEO George Chen, MD (ex-AstraZeneca, 70+ INDs and 30+ NDAs directed) and co-founder/CFO/CBO John Jin, PhD (ex-BeiGene), with Antoine Yver, MD (former Daiichi Sankyo EVP) on the board.

D3 Bio firmographics

Firmographics
Name
D3 Bio
Legal name
D3 Bio, Inc.
Website
https://d3bio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
D3 Bio is a clinical-stage biotechnology company developing next-generation KRAS inhibitors and targeted oncology therapeutics. Headquartered in Shanghai with R&D in Wuxi, China, it is advancing its lead asset elisrasib into global Phase III trials for KRAS G12C-mutant lung, colorectal, and pancreatic cancers.
Ownership category
akta.pro rank

D3 Bio industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Oncology drug development
  • KRAS inhibitor therapy
  • Targeted cancer therapeutics
  • Clinical-stage biotechnology
  • Precision oncology medicines

Where D3 Bio is headquartered

Location

Headquarters

HQ city
Wuxi Shi
HQ country
China
HQ region
Asia

Offices2 records

Markets served

D3 Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: As a clinical-stage biotechnology company, D3 Bio's revenue model is based on developing and commercializing innovative oncology therapeutics. The company is advancing its pipeline through clinical trials toward regulatory approvals for global commercialization. The company owns global rights to all programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

D3 Bio product offering

Product offering

Core offering

D3 Bio is a clinical-stage biotechnology company developing precision oncology therapeutics, with lead asset elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor in global Phase III trials. The pipeline also includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody), each targeting tumor-driving mutations or immune pathways.

Product overview

D3 Bio is a clinical-stage biotechnology company developing a pipeline of oncology therapeutics targeting KRAS mutations and immune pathways. The core product is Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. The pipeline includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody). All programs target driver mutations or critical immune pathways with first-in-class or best-in-class potential, and D3 Bio owns global rights to all programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Elisrasib (D3S-001) Next-generation GDP-bound KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. Covalently binds the GDP-bound (OFF) form of KRAS G12C, blocking nucleotide cycling and suppressing oncogenic signaling. Being evaluated in global Phase II/III clinical trials for NSCLC, CRC, and pancreatic cancer.
  • D3S-002 ERK1/2 inhibitor for vertical inhibition of the MAPK pathway to improve anti-tumor activity and overcome resistance to KRAS G12C inhibitors. IND cleared by FDA.
  • D3S-003 KRAS G12D inhibitor for KRAS-driven cancers. FDA IND cleared for Phase 1 trial.
  • D3L-001 HER2×CD47 bispecific antibody that enhances phagocytosis and eradication of HER2-positive solid tumors via HER2 guided CD47 co-blocking. IND cleared by FDA for Phase 1 trial.

Companies that use D3 Bio

Customer profile

Segments4 records

Ideal customer profiles1 record

D3 Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

D3 Bio partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

D3 Bio competitors and assessment

Company assessment

Direct peers

  • Mirati Therapeutics (acquired by Bristol Myers Squibb): Developed Krazati (adagrasib), a KRAS G12C inhibitor that received accelerated FDA approval in December 2022 for NSCLC and is in development for CRC and other KRAS G12C-mutated tumors. Mirati is the most direct mechanistic competitor to elisrasib in the same target and indication space.
  • Revolution Medicines: Clinical-stage oncology biotech developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C(ON)), which target the active GTP-bound state of RAS. Its next-generation mechanism could leapfrog elisrasib's GDP-bound approach.
  • Erasca: Clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway, including ERK inhibitors and KRAS-targeting agents. Erasca's pipeline focus on the same signaling pathway makes it a direct mechanistic peer to D3 Bio's MAPK cascade strategy.

Broad incumbents

  • Amgen: Developed Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor (May 2021), with established commercial infrastructure in oncology. As the incumbent in KRAS G12C, Amgen represents the primary benchmark for elisrasib's clinical and commercial performance.
  • AstraZeneca: Global pharmaceutical company with major oncology franchise and established KRAS programs (including Datroway and earlier-stage assets). D3 Bio's leadership including George Chen and Antoine Yver previously held senior oncology roles at AstraZeneca, providing direct relevance to its development approach.

Emerging players

  • BridgeBio Pharma: Through its oncology subsidiary has pipeline programs targeting KRAS and the MAPK pathway. BridgeBio's clinical-stage KRAS efforts overlap with D3 Bio's vertical MAPK inhibition strategy.

Regional players

  • BeiGene: Chinese-founded global oncology biotech with deep China-US clinical development capabilities, including Brukinsa (zanubrutinib). BeiGene shares the same founder/leadership DNA (George Chen and John Jin previously held senior roles at BeiGene) and similar global ambitions from a Chinese base.
  • Innovent Biologics: Chinese clinical-stage biotech developing oncology therapeutics including PD-1 and KRAS-targeted therapies, with global development ambitions. Comparable as a China-anchored oncology biotech pursuing US/EU regulatory pathways.
  • Junshi Biosciences: Chinese clinical-stage biotech with oncology pipeline including the PD-1 toripalimab and KRAS-targeting programs. Comparable as a Chinese biotech pursuing global oncology development and US regulatory approvals.
  • Zai Lab: China-US biotech developing and commercializing innovative oncology therapeutics globally, including licensed and proprietary assets. Comparable business model as a Chinese-anchored oncology company pursuing US/China dual development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

D3 Bio social profiles

Digital presence

D3 Bio compliance and trust

Trust signal

Compliance7 records

D3 Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

D3 Bio leadership team

Management profile

Number of profiles

Profiles3 records

D3 Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

D3 Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D3 Bio

What does D3 Bio do?

D3 Bio is a clinical-stage biotechnology company developing precision oncology therapeutics, with lead asset elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor in global Phase III trials. The pipeline also includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody), each targeting tumor-driving mutations or immune pathways.

Is D3 Bio a public or private company?

D3 Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was D3 Bio founded?

D3 Bio was founded in 2020. It employs 1 to 10 people.

Where is D3 Bio based?

D3 Bio is headquartered in Wuxi Shi, China, in the Asia region.

How does D3 Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are D3 Bio's main competitors?

Direct peers on record are Mirati Therapeutics (acquired by Bristol Myers Squibb), Revolution Medicines and Erasca. Broad incumbents are Amgen and AstraZeneca. BridgeBio Pharma is listed as an emerging player. Regional players are BeiGene, Innovent Biologics, Junshi Biosciences and Zai Lab.

Does D3 Bio have an API?

No public API is recorded for D3 Bio.

What industry is D3 Bio in?

D3 Bio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldD3 Bio synthesizes new pan-KRAS inhibitorsD3 Bio (Wuxi) Co. Ltd. has prepared and tested new pan-GTPase KRAS inhibitors, which are potentially useful for cancer treatment. The company's development of these inhibitors is reported in a BioWorld Science article dated August 14, 2026.AijournD3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLCD3 Bio presented first-line clinical data for its next-generation KRAS G12C inhibitor elisrasib (D3S-001) at ASCO 2026, showing monotherapy achieved a 78.0% overall response rate and 12.4-month median progression-free survival in previously untreated KRAS G12C-mutant NSCLC patients (n=41). The combination therapy with pembrolizumab demonstrated an 81.3% ORR with a 12-month PFS rate of 53.7% in first-line NSCLC (n=48), with favorable safety profiles supporting Phase 3 randomized study evaluation.PR Newswire APACD3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLCD3 Bio presented first-line data for elisrasib monotherapy and combination with pembrolizumab in KRAS G12C-mutant NSCLC at ASCO 2026. Monotherapy showed an ORR of 78.0% and median PFS of 12.4 months, while the combination achieved an ORR of 81.3% and a 12-month PFS rate of 53.7%. The company plans to accelerate Phase 3 evaluation.BioSpaceD3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLCD3 Bio presented first-line data for elisrasib in KRAS G12C-mutant NSCLC at ASCO 2026. Monotherapy showed an ORR of 78.0% and median PFS of 12.4 months, while the combination with pembrolizumab achieved an ORR of 81.3% and a 12-month PFS rate of 53.7%. The company plans to accelerate Phase 3 evaluation.PR NewswireD3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLCD3 Bio presented first-line clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 ASCO Annual Meeting in Chicago, showing monotherapy achieved a 78.0% ORR with 12.4 months median PFS in untreated KRAS G12C-mutant NSCLC patients (n=41), while combination with pembrolizumab achieved an 81.3% ORR with a 53.7% 12-month PFS rate (n=48). The company stated these results, demonstrating favorable safety profiles across all PD-L1 expression levels, support advancement to Phase 3 randomized studies, with 60.5% of monotherapy and 82.7% of combination therapy patients remaining on treatment at data cutoff.Phirda300多亿美元当红Biotech,遇上中国劲敌?D3 Bio's KRAS G12C inhibitor elisrasib showed higher response rates and longer progression-free survival than competitors in pancreatic, lung, and colorectal cancer trials. CEO Chen Zhijian said pan-RAS inhibitors may face market adjustment once allele-specific G12D inhibitors are approved, and the company is developing G12D and G12V inhibitors.PR NewswireD3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor TypesD3 Bio announced Phase 2 clinical data for elisrasib (D3S-001), a next-generation KRAS G12C inhibitor, at AACR 2026, showing strong efficacy across NSCLC (58.8% ORR, 12.2 months mPFS), CRC (46.9% monotherapy ORR, 62.1% with cetuximab combination), and pancreatic cancer (65.0% ORR, 13.5 months mPFS). The drug also demonstrated meaningful activity in patients previously treated with first-generation KRAS G12C inhibitors, including those with KRAS gene amplification. Elisrasib showed a favorable safety profile with Grade 3+ treatment-related adverse events between 8.7% and 15.6% across indications.PR Newswire APACD3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor TypesD3 Bio presented phase 2 data for elisrasib (D3S-001) at AACR 2026, showing efficacy across KRAS G12C-mutant solid tumors. In KRAS G12C inhibitor-naïve NSCLC, elisrasib achieved an ORR of 58.8% and mPFS of 12.2 months, while in PDAC it showed an ORR of 65.0% and mPFS of 13.5 months. The company plans further studies to optimize combination strategies.PR NewswireD3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary SessionD3 Bio Inc., a Shanghai-based clinical-stage biotechnology company, announced that five abstracts have been accepted for presentation at the AACR Annual Meeting 2026 in San Diego, California, with two selected for oral presentations at Clinical Trials Plenary Sessions. The presentations will showcase data from D3 Bio's KRAS-targeted pipeline, including Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor in Phase 1/2 trials, D3S-002, a selective ERK1/2 inhibitor, and D3S-003, an orally bioavailable KRAS G12D inhibitor in early-stage development. The company stated these data highlight its scientific progress in advancing transformative therapies for KRAS-driven cancers.